Iktos
AI-driven de novo drug design and automated retrosynthesis for accelerated medicinal chemistry.
Updated 13d ago
Has API
PricingFree
Free
De novo molecular design
Retrosynthesis planning
Multi-parametric optimization
About Inceptive
Inceptive is a pioneering biotechnology company that leverages advanced artificial intelligence to design novel biological molecules, with a primary focus on RNA therapeutics and vaccines. Co-founded by Jakob Uszkoreit, a co-inventor of the foundational Transformer AI architecture, Inceptive utilizes highly specialized deep learning models to understand and predict the complex rules of RNA folding, structure, and function. The platform does not rely solely on theoretical computation; it tightly integrates state-of-the-art computational design with a high-throughput, automated wet-lab experimental loop. This closed-loop system allows the AI to continuously learn from massive amounts of real-world biological data generated in-house, rapidly iterating on RNA designs to optimize for critical therapeutic factors like stability, translation efficiency, and immunogenicity. By treating biology as a programmable language, Inceptive partners with leading pharmaceutical companies to accelerate the drug discovery pipeline, turning what traditionally takes years of trial and error into a highly predictable, computational process. The ultimate goal is to enable the rapid development of next-generation mRNA vaccines, protein replacement therapies, and novel treatments for currently undruggable diseases.
Core Capabilities
Inceptive is a pioneering biotechnology company that leverages advanced artificial intelligence to design novel biological molecules, with a primary focus on RNA therapeutics and vaccines.
